Discovery of antibiotic lolamicin that targets deadly bacteria without harming gut microbiome

FHS
June 4, 2024
5:05 am

Researchers discovered lolamicin, a selective Gram-negative antibiotic, effective against multidrug-resistant pathogens while sparing the gut microbiome.

Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell lymphoma

December 29, 2023

NIH renews support for UMass Chan and UMass Lowell’s point-of-care technology initiative

UMass Chan Medical School and UMass Lowell have received an $8.9 million award from the National Institutes of Health (NIH) for renewed support of their

October 20, 2023

Scientists identify over 5000 high-risk cancer gene variants

Over 5,000 genetic variants that enable certain cancers to thrive have been identified by scientists, along with a potential therapeutic target to treat or even

July 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.